About Andy Schmeltz

I lead the team responsible for Pfizer’s industry-leading portfolio of innovative cancer medicines and biosimilars. People living with cancer are the reason we persevere as we search for new medicines. They drive us every day.

During my time as the Global President and General Manager of Pfizer Oncology, the business has experienced tremendous and continued growth. In 2019, I championed the $11.4 billion acquisition of Array BioPharma Inc. to strengthen the division’s leadership in cancer care and expand the company’s portfolio into additional areas of unmet medical need. And in 2020, our portfolio of 24 innovative cancer medicines and biosimilars reached over 716,000 people around the world living with more than 30 types of cancer.

Over the last 25 years working in the healthcare industry, I’ve had the opportunity to hold multiple leadership positions. As a leader, I believe my most important job is to set a compelling vision that instills purpose and create an open culture where people feel inspired and can be their best selves.

At Pfizer Oncology, we are rallied behind the belief that we can help change the story of cancer from loss to hope – and, one day, find cures for this deadly disease.